Chinese Medical Industry Seeks Avenues To Globalize
This article was originally published in PharmAsia News
Executive Summary
China's export of medical products has always exceeded its import, and trade surplus of the sector hit a new high last year. However, 2007 marked a turning point as the import growth rate overtook export increase for the first time by 1.5 percent. The president for the China Chamber of Commerce of Medicines and Health Products Importers and Exporters notes that rising internal competition and the impact of various health policies coming into effect mean globalization is the way to go. In the face of more challenges, domestic companies have to innovate and develop multiple markets. Some tap into foreign investors to list on overseas stock exchanges as an internationalization strategy. (Click here for more - Chinese Language)
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.